POINT BIOPHARMA GLOBAL INC. Comprehensive Income
POINT BIOPHARMA GLOBAL INC. reported Comprehensive Income of -$25.14 million for the 3-month period ending 2023-09-30, per its 10-Q filed 2023-11-13.
Discontinued › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2023-11-13
- POINT BIOPHARMA GLOBAL INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2023-09-30 was -$25.14M.
- POINT BIOPHARMA GLOBAL INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2023-06-30 was -$26.22M.
- POINT BIOPHARMA GLOBAL INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2023-03-31 was -$16.33M.
- POINT BIOPHARMA GLOBAL INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2022-12-31 was $163.42M.
- POINT BIOPHARMA GLOBAL INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was $97.84M.
- POINT BIOPHARMA GLOBAL INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2021 was -$45.90M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2023-09-30 | -$25.14M 10-Q · filed 2023-11-13 | -$51.36M derived: sum of 2 quarters · filed 2023-11-13 | -$67.69M 10-Q · filed 2023-11-13 | $95.73M derived: sum of 4 quarters · filed 2023-11-13 |
| 2023-06-30 | -$26.22M 10-Q · filed 2023-08-14 | -$42.55M 10-Q · filed 2023-08-14 | $120.87M derived: sum of 3 quarters · filed 2023-08-14 | $96.59M derived: sum of 4 quarters · filed 2023-11-13 |
| 2023-03-31 | -$16.33M 10-Q · filed 2023-05-15 | $147.09M derived: sum of 2 quarters · filed 2023-05-15 | $122.81M derived: sum of 3 quarters · filed 2023-11-13 | $97.89M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-12-31 | $163.42M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-27 | $139.14M derived: sum of 2 quarters · filed 2023-11-13 | $114.22M derived: sum of 3 quarters · filed 2023-11-13 | $97.84M 10-K · filed 2023-03-27 |
| 2022-09-30 | -$24.28M 10-Q · filed 2023-11-13 | -$49.20M derived: sum of 2 quarters · filed 2023-11-13 | -$65.58M 10-Q · filed 2023-11-13 | -$79.78M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | -$24.92M 10-Q · filed 2023-08-14 | -$41.30M 10-Q · filed 2023-08-14 | -$55.50M derived: sum of 3 quarters · filed 2023-08-14 | -$72.62M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | -$16.38M 10-Q · filed 2023-05-15 | -$30.58M derived: sum of 2 quarters · filed 2023-05-15 | -$47.69M derived: sum of 3 quarters · filed 2023-05-15 | -$56.50M derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | -$14.20M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-27 | -$31.31M derived: sum of 2 quarters · filed 2023-03-27 | -$40.12M derived: sum of 3 quarters · filed 2023-03-27 | -$45.90M 10-K · filed 2023-03-27 |
| 2021-09-30 | -$17.12M 10-Q · filed 2022-11-14 | -$25.92M derived: sum of 2 quarters · filed 2022-11-14 | -$31.71M 10-Q · filed 2022-11-14 | |
| 2021-06-30 | -$8.80M 10-Q · filed 2022-08-12 | -$14.59M 10-Q · filed 2022-08-12 |